Your session is about to expire
← Back to Search
Proteasome Inhibitor
Mezigdomide + Carfilzomib + Dexamethasone for Multiple Myeloma (SUCCESSOR-2 Trial)
Phase 3
Recruiting
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 5 years
Awards & highlights
SUCCESSOR-2 Trial Summary
This trial is testing a new drug, CC-92480, to see if it is more effective than the current standard of care for treating myeloma.
Who is the study for?
This trial is for individuals with multiple myeloma who've had at least one prior treatment, including lenalidomide and an anti-CD38 monoclonal antibody. They should have shown some response to previous treatments and must have disease progression after the last regimen. Those previously treated with mezigdomide or carfilzomib, or recent stem cell transplant recipients cannot participate.Check my eligibility
What is being tested?
The SUCCESSOR-2 study is testing Mezigdomide combined with Carfilzomib and Dexamethasone (MeziKD) against just Carfilzomib and Dexamethasone (Kd). The goal is to see which combination works better for relapsed or refractory multiple myeloma.See study design
What are the potential side effects?
Potential side effects include immune system suppression leading to infections, blood clots, fatigue, nausea, diarrhea, muscle pain, fever from infusion reactions. Long-term risks may involve bone marrow suppression causing anemia or bleeding problems.
SUCCESSOR-2 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to approximately 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Progression-free Survival (PFS)
Secondary outcome measures
Change From Baseline in the European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30)
Change From Baseline in the European Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20)
Complete Response (CR) Or Better (CRR)
+12 moreSUCCESSOR-2 Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)Experimental Treatment3 Interventions
Group II: Kd (Carfilzomib + Dexamethasone)Active Control2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dexamethasone
2007
Completed Phase 4
~2590
Mezigdomide
2023
Completed Phase 1
~40
Carfilzomib
2017
Completed Phase 3
~1440
Find a Location
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,641 Previous Clinical Trials
4,129,539 Total Patients Enrolled
87 Trials studying Multiple Myeloma
29,395 Patients Enrolled for Multiple Myeloma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have previously been treated with mezigdomide or carfilzomib.I have been treated with lenalidomide and an anti-CD38 drug for at least 2 cycles.I have been diagnosed with multiple myeloma and it can be measured.I have undergone treatment for myeloma before.My myeloma has worsened despite my last treatment.I have seen improvement in my myeloma after treatment.I have had a stem cell transplant from a donor or my own within the last 12 weeks.
Research Study Groups:
This trial has the following groups:- Group 1: MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)
- Group 2: Kd (Carfilzomib + Dexamethasone)
Awards:
This trial has 2 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What are the dangers that 480Kd (CC-92480 + Carfilzomib + Dexamethasone) poses to patients?
"3."
Answered by AI
How many people fit the qualifications for this experiment?
"The sponsor, Bristol-Myers Squibb, needs to enroll 525 eligible patients from various hospitals including Local Institution - 0186 in Montreal and Local Institution - 0184 in Toronto."
Answered by AI
Are we currently looking for new participants in this clinical trial?
"From what is published on clinicaltrials.gov, this particular trial is ongoing and looking for more patients as of 11/15/2022--the date the listing was first created and also the date of the most recent edit."
Answered by AI
Where are the sites of this study?
"There are 11 total sites for this study, with some of them being in Montreal, Toronto and Augusta. If you enroll in the study, it will be most convenient for you to choose a location nearest to where you live to limit travel demands."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger